Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: A preliminary animal study

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 5, 2010, Pages 539-543

  Subramanian, Suresh ^a   Das, Tapas ^a   Chakraborty, Sudipta ^a   Sarma, Haladhar Dev ^a   Banerjee, Sharmila ^a   Samuel, Grace ^a   Venkatesh, Meera ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; hepatocellular carcinoma; lipiodol; radioembolization

Indexed keywords

8 QUINOLINOL; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL 8 QUINOLINOL LU 177; TRACER; UNCLASSIFIED DRUG; (177)LU OXINE LIPIODOL; (177)LU-OXINE-LIPIODOL; DIETHYLNITROSAMINE; ETHIODIZED OIL; LUTETIUM; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; ISOTOPE LABELING; LIVER CELL CARCINOMA; NEUTRON RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SKELETON; WHOLE BODY SCINTISCANNING; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG SCREENING; LIVER TUMOR; SYNTHESIS; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; DRUG EVALUATION, PRECLINICAL; ETHIODIZED OIL; IODIZED OIL; ISOTOPE LABELING; LIVER NEOPLASMS, EXPERIMENTAL; LUTETIUM; OXYQUINOLINE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 77958180017     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0792     Document Type: Article

References (20)

1. Greten FT, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol 2006;45:868.
2. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907.
4. Sundaram FX. Radionuclide therapy of hepatocellular carcinoma. Biomed Imaging Interv J 2006;2: e40.
5. Sangro B, Bilbao JI, Iñarrairaegui M, et al. Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres. Dig Dis 2009;27:164.
6. Palma LD. Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Br J Radiol 1998;71:808.
7. 188Re-SSS lipiodol: Radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Commun 2004;25:1007.
8. 131I-Lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med 2004;45:612.
9. Risse JH, Grunwald F, Kersjes W, et al. HCC Intraarterial therapy with I-131-Lipiodol. Cancer Biother Radiopharm 2000;15:65.
10. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: An activity escalation study. Eur J Nucl Med Mol Imaging 2006;33:344.
11. 188Re-HDD-labeled iodized oil for treatment-prospective multicenter clinical trial. Radiology 2007;243:509.
12. 188Relabelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 2006;27:223.
13. 166Ho-oxine-lipiodol and its preliminary bio-evaluation for potential application in therapy of liver cancer. Nucl Med Commun 2009;30:362.
14. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010;40:105.
15. 188Re-lipiodol: Preclinical therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun 2004;25:691.
16. 90Y-oxine-ethiodol, potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isot 2003;58:567.
17. 177Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109.
18. 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol 2008;35:589.
19. Draye M, Thomas S, Cote G, et al. Cloud point extraction for selective removal of Gd (III) and Ln (III) with 8-hydroxyquinoline. Sep. Sci Technol 2005;40:611.
20. Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985;154:25.